We would love to hear your thoughts about our site and services, please take our survey here.
And what happens if that doesn’t materialise?
So what are you going to do FX?
It’s all about messaging that they are currently in on-going discussions with potential partners on two fronts.
https://www.***************************/nuformix-excited-as-it-moves-focus-to-nxp002-and-nxp004-programmes/4121127409
on directors talk interviews if link is blocked
Video interviews are usually done on the morning and posted in the afternoon. They need editing etc, so not instant.
As I mentioned a couple of months ago, Oxilio have likely around £700k cash, so it was never going to be huge amounts.
I reckon circa 100k they will have paid for the patents. (Based on nothing but my own guesstimate)
Would have hoped they’d go for more like 500k but as NfX have kept the royalty side in place I doubt it.
Also Oxilio have recently employed a Clinical Trials Administrator, so they signs are it’s moving forward soon.
Good to see them getting some form of immediate payment for nxp001 although undisclosed.
I see Small Pharma, the company Alastair Riddell scarpered to has been bought up by Cybin for around £17m.
https://smallpharma.com/press-release/cybin-to-acquire-small-pharma/
And Gisli Jenkins who was previously a consultant to Nuformix
https://ipf-summit.com/speaker/gisli-jenkins/
Author disclosures: R.G.J. received research support from Biogen, Galecto, GlaxoSmithKline, and Novartis Pharma; served on an advisory committee for Biogen, Boehringer Ingelheim, GlaxoSmithKline, InterMune, PharmAkea, and Roche; served as a consultant and as a speaker for Roche; served as a speaker for InterMune; served as a consultant for Nuformix and Pulmatrix; and served on a data and safety monitoring board for Boehringer Ingelheim.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5800895/
Also gives a quote in the original rns in March 2021
Dr Lee Borthwick, Senior Lecturer in Fibrosis Biology at the Newcastle Fibrosis Research Group, Newcastle University, said: "The data from this most recent study of Nuformix's drug candidate, NXP002, are very encouraging in combination with current IPF drugs and show clear attenuation of both fibrosis and inflammatory markers in combination with pirfenidone or nintedanib. This reinforces previous work done in our laboratories on this compound."
Dr Anne Brindley, CEO of Nuformix, said: "IPF is a devastating disease with few treatment options and there is a real need for new therapies that are efficacious but that have better tolerability than the current therapies on the market. IPF is likely to become a combination market in the future. The results of this ex-vivo study in IPF are very encouraging and suggest the potential benefit of using NXP002 in combination with standard of care treatments for IPF. These results underpin NXP002's potential and demonstrate that further development of NXP002 for the treatment of IPF is warranted."
Lee is also the founder of Fibrofind and is speaking at the IPF summit in Boston in a couple of weeks about the use of human precision cut lung tissue samples, basically about the Nuformix work he’s been doing.
https://ipf-summit.com/speaker/lee-borthwick/
Timing not in the hands of the company, more by pure chance than anything else.
Interesting that this patent relates to the announcement of 2 March 2021 and was filed before Dans return.
Https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2023161668&_cid=P10-LM7XQB-09920-1
Abstract
The treatment of idiopathic pulmonary fibrosis (IPF) using a therapeutically effective amount of a combination of tranilast and pirfenidone, or a therapeutically effective amount of a combination of tranilast and nintedanib, is described. Tranilast may be administered as an adjunctive therapy to the treatment of IPF by either pirfenidone or nintedanib. The combination of tranilast and pirfenidone and the combination of tranilast and nintedanib may also be synergistically effective to treat IPF. Methods and pharmaceutical compositions for treating idiopathic pulmonary fibrosis (IPF) are also described
"Did this Dan fellow say ethics would not allow a stand alone clinical trial or not ?"
No he didn't say that.
He said they would be ticking that box.
(transcript from last presentation)
"...we've done a lot of that precursive work already we've seen no sort of issues in terms of any sort of tolerability red flags or anything like that so that that's simply a data package that needs to be acquired in order to move into a human studies"
Over to you Mulder, back up your statement with evidence.
Such a shame Mulder is to spineless to make their case face to face.
Just another weekend keyboard warrior.
Tried to tell us nxp004 couldn’t possibly be based on Olaparib and was wrong.
Tried to tell us that no auditor would go near the company and was wrong.
Tried posting under another username and got caught.
Thanks Mulder, I guess you don’t have the guts to ask the questions to the company.
Shame your chicken.
I take it Mulder you will be at Thursdays AGM to put this to the company face to face?
Galecto has tanked after its inhaled IPF therapy was pulled at phase II. I think this only leaves one inhaled IPF therapeutic ongoing after stage 1.
https://www.thepharmaletter.com/article/galecto-tanks-as-phase-iib-trial-of-gbo139-fails
Ok let’s say £260k cash in bank, add £70k placing money, add £70k Lanstead payments (with a further £45k likely up to October) plus £87.5k money from warrants.
So circa £530k available.
Current liabilities are £270k so if these are r&d then they can claim 30% cash from the government for this. So effectively pay £162k for the tissue work.
£530k deduct £162k gives £368k.
Over to you NFT.
Like all good teachers say… show me your working out.